

## Dr. Degar et al reply

*To the Editor:*


We thank Drs. Rousset and Ray for their comment<sup>1</sup> on our manuscript and for highlighting the importance of a consensus-driven, multidisciplinary approach to the management of patients with hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS).<sup>2</sup>

As Rousset and Ray note,<sup>1</sup> the nature of MAS-HLH lends itself to the need for input from many subspecialties and a predetermined approach to the diagnosis and treatment of affected patients. The presentation of MAS-HLH can be pleomorphic, ranging from the classic presentation of multisystem dysfunction to organ-specific manifestations such as central nervous system (CNS)-isolated HLH.<sup>3,4</sup> It can occur in the setting of a genetic condition (familial HLH) or secondary to an infection, rheumatologic condition, or malignancy. Thus, multiple stakeholders need to be engaged to recognize MAS-HLH in its various forms and to treat the resulting multiorgan involvement. The hyperinflammation that is characteristic of MAS-HLH is often easier to manage earlier in the disease course and will progress at a relentless pace until sufficient immunosuppression is implemented. Thus, timely recognition and prompt treatment of MAS-HLH is paramount. Yet, treatment approaches for MAS-HLH include chemotherapy-based protocols and/or cytokine-directed therapies with almost no comparative studies to evaluate these approaches.<sup>5–8</sup> It can therefore be difficult for providers from different subspecialties to agree upon an initial therapeutic strategy given the lack of data in the field. It is for these reasons that multidisciplinary teams and an agreed-upon management approach are particularly important in MAS-HLH.

Rousset and Ray note several features of their multidisciplinary team for MAS-HLH that were also important for success at our institution.<sup>2,9</sup> The first is continued engagement of a group of pediatric subspecialties with an interest and expertise in MAS-HLH. Second, this MAS-HLH workgroup developed consensus on a diagnostic and treatment approach for patients with MAS-HLH that was workable at their institution. Finally, infrastructure was put in place to facilitate communication (email list servers, newsletters) and implementation of the MAS-HLH guideline (electronic order sets). It is likely that implementing these fundamentals will be helpful for other clinicians who are seeking to create similar multidisciplinary teams.

Our experience, coupled with that of Rousset and Ray, emphasizes the importance of multidisciplinary teams in the management of children with immune dysregulation. Swigart et al recently reported on the successful development of a multidisciplinary, inpatient consult service for children with sepsis and multiorgan dysfunction syndrome.<sup>10</sup> During the coronavirus disease 2019 (COVID-19) pandemic, many pediatric institutions developed a similar multispecialty approach to

the management of children with multisystem inflammatory syndrome. The development, structure, and scope of these types of collaborative and multidisciplinary teams vary across institutions. Some teams address a single syndrome, like MAS-HLH, whereas others encompass the broader phenotype of immune dysfunction. The approach to such a team can be semiformal or highly structured. At certain hospitals, there is strong institutional support and resources whereas others, as noted by Rousset and Ray, do not enjoy this luxury. There is no one-size-fits-all approach that will work. Instead, the secret to success seems to be the willingness of a group of motivated clinicians to improve care for children with complex immune conditions through ongoing communication, organization, and guideline development. Once formed, these groups can provide the foundations needed to track outcomes, establish research initiatives, create educational opportunities, and offer long-term follow-up for patients. Although there is a continued need to demonstrate that multidisciplinary teams improve outcomes, there is increasing evidence that this approach benefits patients and providers alike and should be the standard of care.

Barbara A. Degar<sup>1</sup>, MD  
Olha Halyabar<sup>2</sup>, MD  
Melissa M. Hazen<sup>2</sup>, MD  
Lauren A. Henderson<sup>2</sup> , MD, MSc

<sup>1</sup>Department of Pediatric Oncology, Dana Farber Cancer Institute;

<sup>2</sup>Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.

This study was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, K08 AR073339-01 (LAH), and the Boston Children's Hospital Department of Medicine Evidence Based Guideline Program (LAH and MMH).

LAH had received salary support from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies. The remaining authors declare no conflicts of interest relevant to this article.

Address correspondence to Dr. L.A. Henderson, 1 Blackfan Circle, Karp Family Research Building, 10th Floor, Boston, MA 02115, USA.  
Email: Lauren.Henderson@childrens.harvard.edu.

## REFERENCES

1. Rousset M, Ray A. Improving outcomes for patients with hemophagocytic lymphohistiocytosis. *J Rheumatol* 2023; 50:967.
2. Taylor ML, Hoyt KJ, Han J, et al. An evidence-based guideline improves outcomes for patients with hemophagocytic lymphohistiocytosis and macrophage activation syndrome. *J Rheumatol* 2022;49:1042-51
3. Jordan MB, Allen CE, Greenberg J, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO). *Pediatr Blood Cancer* 2019;66:e27929.
4. Li H, Benson LA, Henderson LA, et al. Central nervous system-restricted familial hemophagocytic lymphohistiocytosis responds to hematopoietic cell transplantation. *Blood Adv* 2019;3:503-7.

5. Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. *New Engl J Med* 2020;382:1811-22.
6. Eloseily EM, Weiser P, Crayne CB, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. *Arthritis Rheumatol* 2020;72:326-34.
7. Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer* 2007;48:124-31.
8. Zhang Q, Zhao YZ, Ma HH, et al. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis. *Blood* 2022;139:3493-504.
9. Halyabar O, Chang MH, Schoettler ML, et al. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. *Pediatr Rheumatology Online J* 2019;17:7.
10. Swigart LR, Sanchez-Pinto LN, Nolan BE, Seed PC, Coates BM. A specialized multi-disciplinary care program for children with sepsis and multiple organ dysfunction-associated immune dysregulation. *Pediatr Res* 2022;91:464-9.